Form SC 13G Sarepta Therapeutics, Filed by: FMR LLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
February 9, 2018 11:51 AM ESTWilliam Blair analyst Tim Lugo came out to deafened Sarepta Therapeutics (NASDAQ: SRPT) following reports of a U.K.-specific hold on further dosing of patients enrolled in Sareptas global Phase III ESSENCE trial of golodirsen.
Lugo sees the concerns as "overblown".
To wit... "We see todays roughly 6% sell-off... More
